Darin Thomas, MD
Internal Medicine · Ferdinand, INNPI 1508967738
Payments from drug & device makers
Across 429 payments — averaging $15.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$739
- Lilly USA, LLC$674
- AstraZeneca$505
- Pfizer$293
- Amgen$285
- plus $3K from 33 others
What the payments were for
- Food & beverage$6,495100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 70 | $1,064 |
| AbbVie | 51 | $739 |
| Lilly USA, LLC | 47 | $674 |
| AstraZeneca | 18 | $505 |
| Pfizer | 20 | $293 |
| Amgen | 21 | $285 |
| GSK | 18 | $266 |
| Johnson & Johnson | 20 | $206 |
| Mylan Specialty L.p. | 13 | $201 |
| Boehringer Ingelheim | 14 | $186 |
| Bayer | 15 | $185 |
| Abbott | 11 | $161 |
| Merck | 10 | $159 |
| Novartis | 11 | $155 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $147 |
| Viatris Specialty LLC | 7 | $134 |
| Sumitomo Pharma America, Inc. | 9 | $132 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $132 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $121 |
| Exact Sciences | 7 | $107 |
| Axsome Therapeutics, Inc. | 5 | $100 |
| Otsuka America Pharmaceutical, Inc. | 5 | $84 |
| Astellas Pharma US Inc | 4 | $54 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $43 |
| Sunovion Pharmaceuticals Inc. | 3 | $42 |
| Amarin Pharma, Inc. | 3 | $40 |
| Kowa Pharmaceuticals America, Inc. | 3 | $37 |
| Phathom Pharmaceuticals, Inc. | 2 | $35 |
| Dexcom, Inc. | 2 | $31 |
| Inspire Medical Systems, Inc. | 1 | $30 |
| Sanofi-aventis U.S. LLC | 2 | $26 |
| Medtronic | 1 | $24 |
| Vertex | 1 | $19 |
| Lundbeck LLC | 1 | $16 |
| KCI USA, Inc. | 1 | $14 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
| Eisai Inc. | 1 | $12 |
| Adlon Therapeutics L.p. | 1 | $12 |
| Corium, LLC | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,495 in reported general payments places this provider in the 90th percentile of 1,747 internal medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 68 | $72,784 |
| JanuviaSitagliptin Phosphate | 73 | $63,290 |
| EliquisApixaban | 58 | $57,890 |
| FarxigaDapagliflozin Propanediol | 33 | $33,913 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $18,722 |
| VraylarCariprazine Hcl | 13 | $18,480 |
| TradjentaLinagliptin | 13 | $16,802 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 63 | $15,447 |
| MounjaroTirzepatide | 14 | $14,954 |
| MyrbetriqMirabegron | 14 | $9,980 |
| Humalog Kwikpen U-100Insulin Lispro | 15 | $6,935 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $5,596 |
| Dexlansoprazole DrDexlansoprazole | 21 | $4,722 |
| Levemir FlexpenInsulin Detemir | 15 | $4,245 |
| Novolog FlexpenInsulin Aspart | 17 | $3,552 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $186 | $89,58681 claims |
| MerckJanuvia, Janumet Xr | $159 | $66,78185 claims |
| PfizerEliquis | $293 | $57,89058 claims |
| AstraZenecaFarxiga | $505 | $33,91333 claims |
| AbbVieVraylar, Synthroid | $739 | $20,06248 claims |
| GSKTrelegy Ellipta | $266 | $18,72220 claims |
| Lilly USA, LLCMounjaro | $674 | $14,95414 claims |
| Astellas Pharma US IncMyrbetriq | $54 | $9,98014 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $14 | $1,937252 claims |
| Sanofi-aventis U.S. LLCLantus | $26 | $1,70411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,747 internal medicine providers in Indiana.
Other internal medicine in Ferdinand
- Robert BuynakValparaiso$24.2M
- Mohammed AllawNewburgh$3.6M
- Raj VuppalanchiIndianapolis$3.4M
- Phillip TothIndianapolis$3.2M
- George CornettFranklin$1.3M
- Ajita NarayanLafayette$951K
- Abhinav SinghGreenwood$738K
- Georgiann LinnemeierIndianapolis$692K
- Wa'el BakdashAnderson$625K
- Rita SchmidSouth Bend$599K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.